TScan Therapeutics(TCRX) - 2022 Q1 - Quarterly Report
TScan Therapeutics(TCRX)2022-05-12 12:01☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...